Pharma & Biotech

While Eli Lilly continues to post impressive prescription figures for its blockbuster weight-loss medications, a growing sense of unease is...

The launch of the highly anticipated Wegovy pill on the Hims & Hers platform has been met with a tepid...

While its financial runway extends into 2028, Precision Biosciences (NASDAQ: DTIL) faces a period of clinical anticipation that is testing...

While Evolent Health reports stronger-than-expected operational results, its stock price tells a starkly different story, collapsing to a fresh annual...

The equity of Sunshine Biopharma continues to face significant selling pressure, with its share price entrenched in a clear downward...

In a strategic move to preserve its position on the Nasdaq exchange, XORTX Therapeutics is implementing a reverse stock split....

Following a period of significant pressure after its founders announced their departure, BioNTech is shifting investor focus back to its...

Positive results from a mid-stage clinical study have prompted several Wall Street research firms to revise their outlook on Ocugen,...

Pharmaceutical giant Eli Lilly is approaching a pivotal regulatory milestone. The U.S. Food and Drug Administration (FDA) is expected to...

In a significant strategic shift, telehealth provider Hims & Hers has officially partnered with pharmaceutical giant Novo Nordisk, marking a...